5/23/2022  5:29:57 PM Chg. +20.00 Volume Bid5:35:16 PM Ask5:35:16 PM Market Capitalization Dividend Y. P/E Ratio
1,758.00GBX +1.15% 57,956
Turnover(GBP): 1.02 mill.
-Bid Size: - -Ask Size: - 3.97 bill.GBP - -

Business description

Hikma Pharmaceuticals plc is a multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three core businesses segments: Branded, Injectables and Generics, based principally in the Middle East and North Africa ("MENA") as well as in the United States and Europe. Branded is the largest business of the group which focuses on the MENA region. Hikma develops, manufactures, and markets branded generics and a portfolio of in-licensed products, many of which are still patent protected. They are manufacturing strong anti-infective franchise and increasing focus on cardiovascular, diabetes and central nervous system (CNS) products. The Injectables business sells specialised generic injectable products globally, with state-of-the-art manufacturing facilities in the US and Europe. The Generics business sells non-injectable generic products in the US, with an increasingly differentiated portfolio and pipeline. In Februar 2016 Hikma acquired Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. from Boehringer Ingelheim. Hikma Pharmaceuticals was established 1978 in Amman, Jordan and is headquartered in London, UK.
 

Management board & Supervisory board

CEO
Siggi Olafsson
Management board
Khalid Nabilsi, Bassam Kanaan, Brian Hoffmann, Henriette Nielsen, Hussein Arkhagha, Majda Labadi, Riad Mishlawi, Said Darwazah, Shahin Fesharaki, Susan Ringdal
Supervisory board
Said Darwazah, Ali Al-Husry, Cynthia Schwalm, Douglas Hurt, Dr. Pamela Kirby, John Castellani, Mazen Darwazah, Nina Henderson, Pat Butler, Peter Speirs, Siggi Olafsson
 

Company data

Name: Hikma Pharmaceuticals plc
Address: 13 Hanover Square,UK-London W1S 1HW
Phone: +44-20-7399-2760
Fax: +44-20-7399-2761
E-mail: -
Internet: www.hikma.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 53.84%
IPO date: -

Investor relations

Name: Susan Ringdal
IR phone: +44-20-7399-2760
IR Fax: +44-20-7399-2761
IR e-mail: investors@hikma.uk.com

Company calendar

CW 32 | 8/4/2022 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

Freefloat
 
53.84%
Darhold Limited
 
26.04%
Capital Group International
 
10.10%
Wellington Management Group LLP
 
5.01%
BlackRock Group
 
5.01%